Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GI-5005 plus peginterferon alfa-2a and ribavirin versus standard of care in genotype 1 chronic hepatitis C
2007-005385-12Phase 2Completed
- Sponsor
- GlobeImmune
- Start
- Apr 2008
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of GI-5005 in Hepatitis C genotype 1 (3 arms), sponsored by GlobeImmune. Primary endpoint: Early virologic response at Week 12. Started Apr 2008; status: completed.
02
Drugs
GI-5005
03
Conditions
Hepatitis C genotype 1
Beyond the preview
Go deeper on 2007-005385-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-005385-12.